EMA recommends new approach to benefit:risk assessment of drugs
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has published its first report on a five-part project that aims to improve and standardise the way in which drug regulators in the European Union assess the relative benefits and risks of medicines.